MedPath

Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Clinical Trials
Related News

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Not Applicable
Not yet recruiting
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Procedure: Hematopoietic Cell Transplantation
First Posted Date
2023-05-18
Last Posted Date
2023-05-18
Lead Sponsor
Ruijin Hospital
Target Recruit Count
52
Registration Number
NCT05863845

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1
Recruiting
Conditions
CBL Syndrome
JMML
Neurofibromatosis 1
JCML
Leukemia, Juvenile Myelomonocytic
Interventions
First Posted Date
2023-05-09
Last Posted Date
2024-11-11
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
58
Registration Number
NCT05849662
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

University of California San Francisco, San Francisco, California, United States

and more 1 locations

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Phase 2
Withdrawn
Conditions
Myelodysplastic Neoplasm
Acute Myeloid Leukemia
Interventions
Drug: 7+3
First Posted Date
2023-04-25
Last Posted Date
2024-02-12
Lead Sponsor
Uwe Platzbecker
Registration Number
NCT05829434

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Phase 1
Recruiting
Conditions
Myelodysplastic Syndromes
Secondary Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Interventions
First Posted Date
2023-04-11
Last Posted Date
2024-05-01
Lead Sponsor
Heinrich-Heine University, Duesseldorf
Target Recruit Count
38
Registration Number
NCT05807932
Locations
🇩🇪

Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany

🇩🇪

Universitätsklinikum Jena - Klinik für Innere Medizin II, Jena, Germany

🇩🇪

Universitätsklinikum Aachen - Med. Klinik IV, Aachen, NRW, Germany

and more 3 locations

Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

Phase 2
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2023-04-07
Last Posted Date
2023-04-07
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
60
Registration Number
NCT05805098
Locations
🇨🇳

Qiu Huiying, Suzhou, Jiangsu, China

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Not Applicable
Not yet recruiting
Conditions
Relapsed/Refractory AML
Interventions
Drug: Granulocyte Colony-Stimulating Factor
First Posted Date
2023-04-07
Last Posted Date
2023-05-06
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
20
Registration Number
NCT05805072
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Not Applicable
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2023-04-06
Last Posted Date
2023-09-21
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
36
Registration Number
NCT05801835
Locations
🇨🇳

Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Phase 2
Withdrawn
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Interventions
First Posted Date
2023-03-13
Last Posted Date
2025-04-22
Lead Sponsor
University of Florida
Target Recruit Count
98
Registration Number
NCT05766514
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Phase 2
Recruiting
Conditions
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Recurrent Acute Leukemia of Ambiguous Lineage
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Lymphoblastic Leukemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Echocardiography
Procedure: Lumbar Puncture
Procedure: Multigated Acquisition Scan
First Posted Date
2023-03-09
Last Posted Date
2025-03-19
Lead Sponsor
Children's Oncology Group
Target Recruit Count
78
Registration Number
NCT05761171
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 66 locations

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Phase 1
Not yet recruiting
Conditions
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
Interventions
Drug: intrathecal chemotherapy
First Posted Date
2023-03-02
Last Posted Date
2024-06-21
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
26
Registration Number
NCT05751044
Locations
🇳🇱

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy